Hemophilia A
Conditions
Keywords
FVIII inhibitors
Brief summary
Hemophilia A is a congenital bleeding disorder caused by deficiency of factor VIII (FVIII) and is treated by replacement therapy with FVIII concentrate. Approximately 30% of people with severe hemophilia A develop neutralizing antibodies, called FVIII inhibitors, which interfere with the function of FVIII concentrates. The reason that some, but not all, people with severe hemophilia A develop inhibitors is incompletely understood. Understanding individual and environmental risk factors is important to be able to prevent and possibly treat inhibitors. This study will look at individual and treatment characteristics in babies with severe hemophilia A who have not yet received treatment with FVIII (called Previously Untreated Patients, or PUPS). Subjects in the study will be asked to provide diaries of treatments, medications, and illnesses. Treatment will be directed by the subjects' physician, but all subjects will receive Advate, a third-generation recombinant FVIII product. Subjects will have blood drawn for laboratory tests, which include studies of the immune system and genetic studies of the FVIII mutation, before and 7-9 days after the first treatment with FVIII, and 5 days (+/-2 days) after the 5th, 10th, 20th, 30th, 40th, and 50th days of treatment with FVIII (exposure days). The duration of the study will be first 50 treatments or 3 years, whichever comes first.
Interventions
usual treatment as directed by treating physician
Sponsors
Rho, Inc.
Baxter Healthcare Corporation
The University of Texas Health Science Center, Houston
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Severe hemophilia A with FVIII activity \< 1% normal * Weight \> 3.5 kg at the time of baseline study evaluation * Informed consent, approved by appropriate Institutional Review Board/Independent Ethics Committee, has been administered, signed, and dated
Exclusion criteria
* Prior exposure to clotting factor concentrates or blood products * Other chronic disease * Currently participating in another investigational drug study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Total number of FOXP3-positive T regulatory cells in the circulation | 50 exposure days to FVIII or 3 years, whichever comes first | FoxP3(a protein involved in immune system responses)-positive T regulatory cells in the circulation will be compared before and after exposure to FVIII. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| FVIII-specific T-cells | 50 exposure days to FVIII or 3 years, whichever comes first | FVIII-specific T-cells will be compared before and after exposure to FVIII |
Countries
Austria, Italy, Netherlands, Sweden, United States
Outcome results
None listed